tiprankstipranks
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD

ACADIA Pharmaceuticals (ACAD) Stock Price & Analysis

2,183 Followers

ACAD Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$14.55 - $33.99
Previous Close$15.88
Volume510.56K
Average Volume (3M)1.64M
Market Cap
$2.50B
Enterprise Value$2.14B
Total Cash (Recent Filing)$532.46M
Total Debt (Recent Filing)$49.19M
Price to Earnings (P/E)
Beta0.66
Jul 31, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding165,220,884
10 Day Avg. Volume1,648,770
30 Day Avg. Volume1,642,862
Standard Deviation0.15
R-Squared0.02
Alpha-0.00135
Financial Highlights & Ratios
Price to Book (P/B)7.14
Price to Sales (P/S)10.94
Price to Cash Flow (P/CF)21.70
P/FCF Ratio21.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.63
Enterprise Value/Gross Profit3.13
Enterprise Value/Ebitda137.85
Forecast
Price Target Upside72.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13

Bulls Say, Bears Say

Bulls Say
Market ShareNuplazid continues to grow market share in PDP market.
Patient AdditionsAcadia has seen net patient additions in each of the last six weeks and expects this trend to continue going forward.
Sales GrowthSince launch, only ~25% of diagnosed Rett patients have been treated with Daybue, indicating a significant untreated diagnosed Rett patient population that can continue to grow Daybue sales.
Bears Say
Discontinuation RateThe absolute number of patients discontinuing Daybue was higher than new additions, impacting net patients on the drug.
Price TargetGiven the challenges with the discontinuation rate of Daybue, the overall slope of the penetration was lowered, resulting in the lowering of the price target to $27.
Sales PerformanceInvestors will likely be disappointed by Daybue sales of $75.9M, which modestly missed Consensus' lower reset expectation of $79.0M due to unexpected seasonal trends.
---

Financials

Annual

Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

ACAD FAQ

What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was $14.55 and its highest was $33.99 in the past 12 months.
    What is ACADIA Pharmaceuticals’s market cap?
    Currently, no data Available
    When is ACADIA Pharmaceuticals’s upcoming earnings report date?
    ACADIA Pharmaceuticals’s upcoming earnings report date is Jul 31, 2024 which is in 36 days.
      How were ACADIA Pharmaceuticals’s earnings last quarter?
      ACADIA Pharmaceuticals released its earnings results on May 08, 2024. The company reported $0.1 earnings per share for the quarter, beating the consensus estimate of $0.049 by $0.051.
        Is ACADIA Pharmaceuticals overvalued?
        According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does ACADIA Pharmaceuticals pay dividends?
          ACADIA Pharmaceuticals does not currently pay dividends.
          What is ACADIA Pharmaceuticals’s EPS estimate?
          ACADIA Pharmaceuticals’s EPS estimate is $0.19.
            How many shares outstanding does ACADIA Pharmaceuticals have?
            ACADIA Pharmaceuticals has 165,220,890 shares outstanding.
              What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
              ACADIA Pharmaceuticals reported an EPS of $0.1 in its last earnings report, beating expectations of $0.049. Following the earnings report the stock price went down -11.208%.
                Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
                Among the largest hedge funds holding ACADIA Pharmaceuticals’s share is Baker Bros Advisors LP. It holds ACADIA Pharmaceuticals’s shares valued at 793M.
                  ---

                  Company Description

                  ACADIA Pharmaceuticals

                  ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
                  ---

                  ACAD Company Deck

                  ---

                  ACAD Earnings Call

                  Q1 2024
                  0:00 / 0:00
                  ---

                  ACAD Stock 12 Month Forecast

                  Average Price Target

                  $27.08
                  ▲(72.26% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","40":"$40","19.75":"$19.75","26.5":"$26.5","33.25":"$33.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$39.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.08,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$27.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,19.75,26.5,33.25,40],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2023","6":"Dec<br/>2023","9":"Mar<br/>2024","12":"Jun<br/>2024","25":"Jun<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.89,16.744615384615386,18.59923076923077,20.453846153846154,22.30846153846154,24.163076923076922,26.017692307692307,27.872307692307693,29.72692307692308,31.58153846153846,33.43615384615384,35.29076923076923,37.145384615384614,{"y":39,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.89,15.827692307692308,16.765384615384615,17.703076923076924,18.64076923076923,19.57846153846154,20.516153846153845,21.453846153846154,22.39153846153846,23.32923076923077,24.266923076923078,25.204615384615384,26.14230769230769,{"y":27.08,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.89,15.052307692307693,15.214615384615385,15.376923076923077,15.53923076923077,15.701538461538462,15.863846153846154,16.026153846153846,16.18846153846154,16.35076923076923,16.513076923076923,16.675384615384615,16.837692307692308,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":24.51,"date":1687478400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.4,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.19,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.79,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.68,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.07,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.6,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.33,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.29,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.01,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.01,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.05,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.89,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Agios Pharma
                  ANI Pharmaceuticals
                  BioCryst
                  Corbus Pharmaceuticals

                  Best Analysts Covering ACAD

                  1 Year
                  Ritu BaralTD Cowen
                  1 Year Success Rate
                  14/23 ratings generated profit
                  61%
                  1 Year Average Return
                  +9.05%
                  reiterated a buy rating 4 months ago
                  Copying Ritu Baral's trades and holding each position for 1 Year would result in 60.87% of your transactions generating a profit, with an average return of +9.05% per trade.
                  Popular Stocks
                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis